[Hu B, et al. Signal Transduct Target Ther. 2020;1a;2a;8b] Inclisiran (Leqvio, Novartis) is an siRNA that specifically targets the human PCSK9 mRNA. Inclisiran first received FDA approval in 2021.

Inclisiran is one of a number of new therapies called small interfering RNA (siRNA) drugs. These treatments essentially ...

The first-in-class, small interfering RNA (siRNA) therapy for cholesterol lowering ... for Regeneron in the same period. Novartis added inclisiran to its pipeline after buying The Medicines ...

GalNAc is a widely used delivery method for siRNA therapies ... and Novartis’s Leqvio (inclisiran). Under the third agreement, insitro and Lilly will collaborate to develop an antibody for ...

Novartis’ near-$10 billion takeover of The Medicines Company last year was focused mainly on one asset – cholesterol-lowering drug inclisiran – and the Swiss pharma is now a step closer to ...

Second, we demonstrated the broad potential utility of our ECO Synthesis platform by successfully synthesizing inclisiran, a commercially approved siRNA drug, by four different methods ranging ...

Reporting in Nature, Kumar and colleagues have now developed a method to target small-interfering RNA (siRNA) to the CNS, providing a safe and non-invasive approach for the delivery of this new ...

Second, we demonstrated the broad potential utility of our ECO Synthesis platform by successfully synthesizing inclisiran, a commercially approved siRNA drug, by four different methods ranging ...